Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
NRC Stock Forecast 2026-2027
$21.94
Current Price
$494.46M
Market Cap
Buy 1
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to NRC Price Targets
+4.8%
To High Target of $23.00
+4.8%
To Median Target of $23.00
+4.8%
To Low Target of $23.00
NRC Price Momentum
+1.3%
1 Week Change
+23.6%
1 Month Change
+46.8%
1 Year Change
+16.9%
Year-to-Date Change
-4.6%
From 52W High of $23.00
+99.2%
From 52W Low of $11.01
📊 TOP ANALYST CALLS
Did NRC Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if National Research is one of their latest high-conviction picks.
Latest NRC Stock Price Targets & Analyst Predictions
Based on our analysis of 1 Wall Street analyst, NRC has a bullish consensus with a median price target of $23.00 (ranging from $23.00 to $23.00). The overall analyst rating is Strong Buy (8.0/10). Currently trading at $21.94, the median forecast implies a 4.8% upside. This outlook is supported by 1 Buy, 0 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Constantine Davides at Citizens, projecting a 4.8% upside. Conversely, the most conservative target is provided by Constantine Davides at Citizens, suggesting a 4.8% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
NRC Analyst Ratings
1
Buy
0
Hold
0
Sell
NRC Price Target Range
Low
$23.00
Average
$23.00
High
$23.00
Current: $21.94
Latest NRC Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for NRC.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Jun 22, 2026 | Citizens | Constantine Davides | Market Outperform | Initiates | $23.00 |
National Research Corporation (NRC) Competitors
The following stocks are similar to National Research based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
National Research Corporation (NRC) Financial Data
National Research Corporation has a market capitalization of $494.46M with a P/E ratio of 56.3x. The company generates $138.64M in trailing twelve-month revenue with a 6.5% profit margin.
Revenue growth is +3.7% quarter-over-quarter, while maintaining an operating margin of +16.0% and return on equity of +41.9%.
Valuation Metrics
Market Cap
$494.46M
Enterprise Value
$563.63M
P/E Ratio
56.3x
PEG Ratio
-1.3x
Price/Sales
3.6x
Growth & Margins
Revenue Growth (YoY)
+3.7%
Gross Margin
+60.8%
Operating Margin
+16.0%
Net Margin
+6.5%
EPS Growth
-44.3%
Financial Health
Cash/Price Ratio
+0.5%
Current Ratio
0.5x
Debt/Equity
578.2x
ROE
+41.9%
ROA
+12.2%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
National Research Corporation (NRC) Business Model
About National Research Corporation
What They Do
Provides healthcare data analytics and insights.
Business Model
The company operates by delivering survey-based analytics and tools that help healthcare systems and providers understand patient experiences and improve care quality. National Research Corporation generates revenue through its comprehensive suite of products and services tailored to various healthcare sectors, enabling clients to enhance patient engagement and operational efficiency.
Additional Information
National Research Corporation is crucial in supporting healthcare organizations in navigating patient-centered care, adapting to industry standards and regulations. Its extensive experience and reliable data empower clients to refine their strategies for improving clinical outcomes and patient satisfaction.
Company Information
Sector
Healthcare
Industry
Health Information Services
Employees
357
CEO
Mr. Trent S. Green
Country
United States
IPO Year
2018
Website
www.nrchealth.comNational Research Corporation (NRC) Latest News & Analysis
Latest News
AtkinsRéalis submits Notice of Intent to U.S. Nuclear Regulatory Commission for CANDU® reactor licensing
23 days ago
Quick Summary
AtkinsRéalis Group Inc. has submitted a Notice of Intent to the U.S. Nuclear Regulatory Commission to license its CANDU® reactor technology, aiming to address rising electricity demand in the U.S.
Why It Matters
AtkinsRéalis' regulatory engagement for CANDU® reactors signals potential growth in the U.S. nuclear market, aligning with rising power demand, which could impact energy sector investments.
Source: PRNewsWire
Market Sentiment:
Neutral
Georgia's Plant Hatch receives 20-year license renewal from the Nuclear Regulatory Commission
1 month ago
Quick Summary
Georgia Power's Edwin I. Hatch Nuclear Plant received NRC approval for license renewals, allowing Unit 1 to operate until 2054 and Unit 2 until 2058.
Why It Matters
The NRC's license renewal for the Hatch Nuclear Plant secures long-term operational stability for Georgia Power, potentially enhancing revenue and investor confidence in the utility sector.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
NRC Health has partnered with the Healthcare Experience Foundation to enhance healthcare experience management, aiding organizations in improving patient care and workforce engagement amid resource constraints.
Why It Matters
The partnership between NRC Health and HXF signals increased focus on healthcare performance improvement, potentially enhancing operational efficiency and patient satisfaction, impacting healthcare stocks.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
The Governance Institute has established a Blue Ribbon Committee on Health System Governance to enhance board assessment practices for not-for-profit health systems amid increasing complexity.
Why It Matters
The formation of the Blue Ribbon Committee on Health System Governance signals potential changes in governance practices, which could impact the operational efficiency and strategic direction of healthcare investments.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
NRC reported a decline in Q1 earnings per share year-over-year due to rising costs, but achieved revenue growth and increased contract value.
Why It Matters
Declining EPS signals potential profitability issues, while revenue growth and strong contract values indicate demand. Investors may reassess growth prospects versus cost pressures.
Source: Zacks Investment Research
Market Sentiment:
Negative
NRC Health (NRC) Q1 2026 Earnings Call Transcript
2 months ago
Quick Summary
NRC Health held its Q1 2026 earnings call, discussing financial performance and operational updates. Further details on revenue and projections were provided during the call.
Why It Matters
NRC Health's Q1 2026 earnings call provides insights into financial performance and future guidance, impacting stock valuation and investor sentiment.
Source: Seeking Alpha
Market Sentiment:
Neutral
Frequently Asked Questions About NRC Stock
What is National Research Corporation's (NRC) stock forecast for 2027?
Based on our analysis of 1 Wall Street analysts, National Research Corporation (NRC) has a median price target of $23.00. The highest price target is $23.00 and the lowest is $23.00.
Is NRC stock a good investment in 2027?
According to current analyst ratings, NRC has 1 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $21.94. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for NRC stock?
Wall Street analysts predict NRC stock could reach $23.00 in the next 12 months. This represents a 4.8% increase from the current price of $21.94. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is National Research Corporation's business model?
The company operates by delivering survey-based analytics and tools that help healthcare systems and providers understand patient experiences and improve care quality. National Research Corporation generates revenue through its comprehensive suite of products and services tailored to various healthcare sectors, enabling clients to enhance patient engagement and operational efficiency.
What is the highest forecasted price for NRC National Research Corporation?
The highest price target for NRC is $23.00 from Constantine Davides at Citizens, which represents a 4.8% increase from the current price of $21.94.
What is the lowest forecasted price for NRC National Research Corporation?
The lowest price target for NRC is $23.00 from Constantine Davides at Citizens, which represents a 4.8% increase from the current price of $21.94.
What is the overall NRC consensus from analysts for National Research Corporation?
The overall analyst consensus for NRC is bullish. Out of 1 Wall Street analysts, 1 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $23.00.
How accurate are NRC stock price projections?
Stock price projections, including those for National Research Corporation, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: July 17, 2026 12:52 PM UTC